
Alectos Therapeutics is a private pharmaceutical company dedicated to the discovery and preclinical development of novel small-molecule therapeutics for neurological diseases. Alectos focuses on identifying and developing innovative disease-modifying strategies to address complex neurological conditions for which there are no effective treatments, including Alzheimer’s disease, Parkinson’s disease, and acute ischemic stroke. The Alectos pipeline is directed towards the development of new agents to treat patients living with neurological disorders. Our glucocerebrosidase 2 (GBA2) program…
Built from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Annual Revenue$10M to $25M
Estimated OwnershipPrivateMatching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.